The GalNAc-conjugated apoC3 siRNA, RBD5044, has demonstrated favourable safety, predictable pharmacokinetic (PK), and durable pharmacodynamic (PD) effects in a first-in-human study.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
